Мы в Telegram
Добавить в список отслеживания
Добавить в портфель
Основные параметры
| Цена последней сделки | 68.22 |
|---|---|
| Код ценной бумаги | PPH |
| Полное наименование | VanEck Vectors Pharmaceutical ETF |
| Объем | 218000000000 |
| Изм за день, % | 0.0 |
| Комиссия | 0.36 |
| Дата основания | Dec 20. 2011 |
| Сайт | ссылка |
| Тип актива | Equity |
| Индекс | MVIS US Listed Pharmaceutical 25 Index |
| Регион | Developed Markets |
| Средний P/E | 24.05 |
| Дивиденды | 1.64 |
| 5 летняя доходность | 26.63 |
| 3 летняя доходность | 26.13 |
| Годовая доходность | 17.93 |
| Бета | 0.88 |
| Валюта | usd |
| Топ 10 эмитентов, % | 50.58 |
| Количество компаний | 25 |
| Изменение цены за день: | 0.52% (67.87) |
|---|
Топ эмитентов
| Эмитент | Доля, % | P/BV | P/S | P/E | EV/Ebitda |
|---|---|---|---|---|---|
| Sanofi | 5.28 | 1.99 | 2.83 | 8.63 | 11.01 |
| PFIZER | 5.23 | 3.4 | 5.13 | 22.6 | 16.42 |
| Novartis | 5.19 | 3.46 | 3.92 | 24.62 | 12.99 |
| Bristol-Myers | 5.13 | 3.88 | 3.44 | 93.81 | 10.01 |
| Merck & Co | 5.09 | 7.63 | 4.02 | 27.45 | 11.46 |
| Johnson & Johnson | 5.06 | 6.75 | 5.17 | 29.44 | 16.06 |
| AstraZeneca PLC | 5 | 8.39 | 4.94 | 41 | 21.56 |
| AbbVie | 4.97 | 14.57 | 4.16 | 39.67 | 12.14 |
| Zoetis | 4.75 | 21.14 | 11.93 | 49.01 | 30.97 |
| AmerisourceBergen | 4.69 | 5.58 | 0.12 | 13.93 | 8.98 |
| McKesson | 4.67 | 4.76 | 0.13 | 13.39 | 9.37 |
| GlaxoSmithKline | 4.62 | 6.26 | 2.67 | 11.72 | 11.36 |
| Eli Lilly and Company | 4.48 | 30.41 | 7.4 | 27.87 | 20.95 |
Похожие ETF
Описание VanEck Vectors Pharmaceutical ETF
This ETF is one of several options for achieving exposure to the pharma industry, a corner of the health care market that is capable of delivering big returns but that also comes with some unique risk factors. Given this investment objective, PPH is probably more useful for those looking to achieve tactical exposure to this specific corner of the market; the appeal to buy-and-holders will be limited since many of the components are included in more broad-based funds.
A couple aspects of PPH are noteworthy. First, though PPH is now structured as a true ETF, it used to be one of the HOLDRS products offered by Merrill Lynch. Some of the concentration that was characteristic of those products remains in PPH; the portfolio is relatively shallow and concentration in the top allocations is significant. Further, PPH includes only U.S. stocks, meaning that some of the biggest players in the pharmaceutical industry are excluded from the underlying portfolio.
PPH is a decent option for pharma exposure, but there are probably some better ETFs out there for tapping into this segment of the market. IHE offers better depth of holdings, while DRGS may be appealing to those looking to achieve truly global exposure.